The phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better than insulin glargine (a long-acting insulin) for type 2 diabetes (T2D). Now new research examining a broad range of potential predictors of sustaining blood sugar control and weight loss indicates that greater weight loss,

Initially approved to treat Type 2 diabetes, Ozempic and Mounjaro also can help people with Type 1 diabetes lose weight and control their blood sugar levels, a new study finds.

Eli Lilly & Co.’s blockbuster obesity shot Zepbound helped people with type 1 diabetes lose more than a fifth of their body weight over a yearlong study, suggesting the drug may help patients with the less common autoimmune form of the disease.